Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Jan 16, 2019
The aim of this study was to develop a specific simulation program for the validation of a cytotoxic compounding robot, KIRO® Oncology, for the preparation of sterile monoclonal antibodies and anti-infectious drugs. The impact of excipient formulatio...
The Journal of thoracic and cardiovascular surgery
Dec 13, 2018
OBJECTIVE: We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess t...
Monoclonal antibodies (mAbs) have become a major class of protein therapeutics that target a spectrum of diseases ranging from cancers to infectious diseases. Similar to any protein molecule, mAbs are susceptible to chemical modifications during the ...
Tissue biomarker scoring by pathologists is central to defining the appropriate therapy for patients with cancer. Yet, inter-pathologist variability in the interpretation of ambiguous cases can affect diagnostic accuracy. Modern artificial intelligen...
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Sep 1, 2025
PURPOSE: With increasing use of human epithelial growth factor receptor two (HER2)-targeted therapies, outcomes for numerous breast cancer patients have improved. Nevertheless, patients with HER2-positive tumours face a comparatively heightened risk ...
This study proposes a novel approach to predict the efficacy of bevacizumab (BEV) in treating peritumoral edema in metastatic brain tumor patients by integrating advanced machine learning (ML) techniques with comprehensive imaging and clinical data. ...
Fumarate hydratase-deficient renal cell carcinoma (FHdRCC) is a rare and aggressive form of kidney cancer that presents significant therapeutic challenges. Due to its rarity, treatment decisions often rely on comprehensive literature reviews to ident...
BACKGROUND: Avelumab first-line (1 L) maintenance is a standard of care for advanced urothelial carcinoma (aUC) based on the JAVELIN Bladder 100 phase 3 trial, which showed that avelumab 1 L maintenance + best supportive care (BSC) significantly prol...
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology
Jan 1, 2024
(Purpose) We performed a clinical retrospective study on the evaluation of pembrolizumab treatment results for advanced urothelial cancer in our hospital. (Materials and Methods) Twenty-seven patients diagnosed with advanced or metastatic urothelial ...
Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs) are tremendous, the design and discovery of new candidates remain a time and cost-intensive endeavor. In this regard, progress in the generation of data describi...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.